Opdivo Qvantig Injection, Solution
Product Images NDC 0003-6120

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Opdivo Qvantig (NDC 0003-6120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oq-os-checkmate-037 (Image 01)

Overall survival Kaplan-Meier curve comparing Nivolumab and Investigator's Choice over months. The y-axis shows probability of survival; the x-axis shows overall survival in months up to 39. A table below the graph lists the number of subjects at risk for each group at different time points.*

FDA Label Image

Nivo-sc-carton (Nivo Sc Carton)

Carton label for OPDIVO QVANTIG injection, solution containing nivolumab and hyaluronidase-nvhy. The label indicates strengths of 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/mL and 2,000 units/mL). It specifies subcutaneous use only, with administration over 3 to 5 minutes. The label includes storage instructions, a barcode, manufacturer info (Bristol-Myers Squibb Company), Rx only designation, and dosage recommendation reference.*

FDA Label Image

Oq-dfs-checkmate-274 (Oq Dfs Checkmate 274)

A Kaplan-Meier survival curve comparing the probability of disease-free survival over months between patients treated with nivolumab and those with placebo. The y-axis shows the probability of disease-free survival from 0.0 to 1.0, and the x-axis shows disease-free survival time in months up to 51. The graph includes the number of subjects at risk for each group at multiple time points.*

FDA Label Image

Oq-dfs-checkmate-577 (Oq Dfs Checkmate 577)

A Kaplan-Meier curve chart illustrating the probability of disease-free survival per investigator over time in months, comparing Nivolumab injection versus placebo. The chart includes survival probability on the y-axis and disease-free survival time in months on the x-axis, with a table of the number of subjects at risk for each group below the graph.*

FDA Label Image

Oq-efs-checkmate-77t (Oq Efs Checkmate 77t)

A Kaplan-Meier survival curve showing event-free survival probability per BICR over months comparing Nivolumab plus platinum-doublet chemotherapy versus placebo plus platinum-doublet chemotherapy. The graph includes survival probabilities on the Y-axis and time in months on the X-axis. The number of subjects at risk at various time points is shown beneath the graph for both groups.*

FDA Label Image

Oq-efs-checkmate-816 (Oq Efs Checkmate 816)

A Kaplan-Meier survival curve comparing event-free survival per BICR over months between two treatment groups: nivolumab plus platinum-doublet chemotherapy and platinum-doublet chemotherapy alone. The graph plots the probability of event-free survival on the vertical axis against months on the horizontal axis, with corresponding numbers of subjects at risk listed below the timeline for each group.*

FDA Label Image

Oq-forest-plot-os-checkmate-057 (Oq Forest Plot Os Checkmate 057)

A forest plot chart showing median overall survival (OS) in months for Nivolumab versus Docetaxel based on PD-L1 expression levels. The plot includes unstratified hazard ratios (HR) with confidence intervals and median OS data for various PD-L1 expression cutoffs (≥1%, <1%, ≥5%, <5%, ≥10%, <10%). The x-axis represents the HR scale from 0.25 to 2.0, indicating favorability towards Nivolumab on the left side.*

FDA Label Image

Oq-forest-plot-pfs-checkmate-057 (Oq Forest Plot Pfs Checkmate 057)

A forest plot chart displaying median progression-free survival (PFS) in months across different PD-L1 expression levels with unstratified hazard ratios (HR) comparing Nivolumab versus Docetaxel treatments. The plot shows HR values and sample sizes for each PD-L1 expression category.*

FDA Label Image

Oq-os-attraction-3 (Oq Os Attraction 3)

A survival curve chart showing the probability of survival (%) over time in months for two groups: Nivolumab and INV choice. The chart includes a number at risk table below, indicating the decreasing number of patients at various time points up to 36 months. Nivolumab shows a generally higher survival probability compared to INV choice throughout the period.*

FDA Label Image

Oq-os-checkmate-017 (Oq Os Checkmate 017)

A Kaplan-Meier survival curve chart showing overall survival probability over 24 months comparing two treatments: nivolumab and docetaxel. The x-axis represents overall survival in months, and the y-axis shows the probability of survival. The chart includes a risk table for each treatment at various time points, indicating the number of patients at risk.*

FDA Label Image

Oq-os-checkmate-025 (Oq Os Checkmate 025)

A Kaplan-Meier survival curve chart comparing overall survival probability over time (months) between two treatments: Nivolumab and Everolimus. The y-axis represents the probability of survival from 0.0 to 1.0, and the x-axis shows time in months from 0 to 33. The chart includes a table below indicating the number of patients at risk at various months for each treatment group.*

FDA Label Image

Oq-os-checkmate-057 (Oq Os Checkmate 057)

A survival curve chart comparing overall survival in months between patients treated with Nivolumab and Docetaxel. The y-axis represents the probability of survival, decreasing from 1.0 to 0. The x-axis covers a timeline up to 27 months. Below the graph, a table shows the number of patients at risk for each treatment at different time points.*

FDA Label Image

Oq-os-checkmate-066 (Oq Os Checkmate 066)

A Kaplan-Meier survival curve showing the probability of survival over 18 months comparing two treatments: Nivolumab and Dacarbazine. The plot includes a table below indicating the number of patients at risk for each treatment group at various time points throughout the study period.*

FDA Label Image

Oq-os-checkmate-067 (Oq Os Checkmate 067)

A line chart depicting the probability of overall survival over months for three groups: Nivolumab, Nivolumab plus Ipilimumab, and Ipilimumab alone. The x-axis represents overall survival in months, and the y-axis shows the probability of overall survival. The chart includes a table indicating the number of subjects at risk for each treatment group at various time points.*

FDA Label Image

Oq-os-checkmate-141 (Oq Os Checkmate 141)

A Kaplan-Meier survival curve showing overall survival probability over 18 months for two groups: nivolumab (black squares) and investigator's choice (INV Choice, black triangles). The plot includes a table of number at risk at various time points for each group, with higher survival probability observed for nivolumab compared to INV Choice across the timeline.*

FDA Label Image

Oq-os-checkmate-214 (Oq Os Checkmate 214)

A Kaplan-Meier survival curve comparing the probability of overall survival over months between two treatment groups: Nivolumab plus ipilimumab and Sunitinib. The graph shows survival probability on the Y-axis and overall survival in months on the X-axis, accompanied by a table listing the number of subjects at risk at various time points for each treatment group.*

FDA Label Image

Oq-os-checkmate-648a (Oq Os Checkmate 648a)

A Kaplan-Meier survival curve graph showing the probability of overall survival over time in months for three treatment groups: nivolumab plus ipilimumab, nivolumab plus chemotherapy, and chemotherapy alone. The x-axis represents overall survival in months, and the y-axis shows the probability of overall survival. The graph includes a legend and a table of the number of subjects at risk at various time points for each treatment group.*

FDA Label Image

Oq-os-checkmate-648b (Oq Os Checkmate 648b)

A survival curve chart comparing the probability of overall survival over months among three treatment groups: Nivolumab plus ipilimumab, Nivolumab plus chemotherapy, and chemotherapy alone. The x-axis represents overall survival in months, and the y-axis represents the probability of overall survival. A table below the graph lists the number of subjects at risk at various time points for each treatment group.*

FDA Label Image

Oq-os-checkmate-649 (Oq Os Checkmate 649)

A survival curve chart comparing the probability of overall survival over time in months between two treatment groups: nivolumab plus chemotherapy and chemotherapy alone. The chart includes a legend and a table listing the number of subjects at risk at various time points for each group. The y-axis represents the probability of overall survival, and the x-axis represents overall survival in months up to 39 months.*

FDA Label Image

Oq-os-checkmate-901 (Oq Os Checkmate 901)

A Kaplan-Meier survival curve comparing overall survival probability over time in months between two treatment groups: nivolumab with gemcitabine plus cisplatin (solid line with triangles) and gemcitabine plus cisplatin alone (dashed line with circles). The chart includes a table of number of subjects at risk at various time points for each group, with survival probabilities decreasing over time for both groups.*

FDA Label Image

Oq-os-pd-l1-cps-greater-than-1-checkmate-649 (Oq Os Pd L1 Cps Greater Than 1 Checkmate 649)

This Kaplan-Meier curve illustrates the probability of overall survival over months for patients treated with nivolumab plus chemotherapy compared to chemotherapy alone. The x-axis shows overall survival in months, and the y-axis shows the probability of overall survival. The graph includes the number of subjects at risk for each treatment group at various time points.*

FDA Label Image

Oq-os-pd-l1-cps-greater-than-5-checkmate-649 (Oq Os Pd L1 Cps Greater Than 5 Checkmate 649)

This figure is a Kaplan-Meier survival curve showing overall survival probability over time in months for two groups: one treated with nivolumab plus chemotherapy and the other with chemotherapy alone. The chart includes data points and a corresponding risk table at the bottom indicating the number of subjects at risk in each group over the study duration up to 39 months.*

FDA Label Image

Oq-pfs-checkmate-648a (Oq Pfs Checkmate 648a)

A Kaplan-Meier survival curve comparing probability of progression-free survival per BICR over months (0 to 39) for three groups: nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy alone. The graph includes a risk table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Oq-pfs-checkmate-648b (Oq Pfs Checkmate 648b)

A Kaplan-Meier plot illustrating the probability of progression-free survival per BICR over 36 months for three treatments: nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy alone. The chart includes a table below displaying the number of subjects at risk for each treatment group over time.*

FDA Label Image

Oq-pfs-checkmate-901 (Oq Pfs Checkmate 901)

A Kaplan-Meier survival curve comparing progression-free survival per BICR (in months) between two treatment groups: Nivolumab with gemcitabine plus cisplatin and gemcitabine plus cisplatin alone. The graph shows probability of progression-free survival on the Y-axis and time in months on the X-axis, with percentage survival decreasing over time. A table below the graph indicates the number of subjects at risk in each group at various time points.*

FDA Label Image

Oq-pfs-checkmate-9er (Oq Pfs Checkmate 9er)

A Kaplan-Meier survival curve chart comparing progression-free survival per BICR in months between two treatment groups: Nivolumab plus Cabozantinib and Sunitinib. The graph plots the probability of progression-free survival on the vertical axis against time in months on the horizontal axis, with subject counts at risk listed below for each group over time.*

FDA Label Image

Oq-rfs-checkmate-238 (Oq Rfs Checkmate 238)

A line graph comparing recurrence-free survival probability over 27 months between two drugs, nivolumab and ipilimumab, in patients. The y-axis shows probability of recurrence-free survival, and the x-axis represents time in months. Nivolumab is indicated by a dashed line with triangle markers, showing higher survival probability, while ipilimumab is shown by a solid line with circle markers, indicating lower survival probability over time. The graph includes a table of the number of subjects at risk at different time points for each drug.*

FDA Label Image

Oq-rfs-checkmate-76k (Oq Rfs Checkmate 76k)

A Kaplan-Meier curve showing the probability of recurrence-free survival over approximately 30 months comparing Nivolumab 480 mg Q4W and placebo. The y-axis represents the probability of recurrence-free survival, and the x-axis represents time in months. The graph includes a table of subjects at risk for each group at various time points.*

FDA Label Image

Oq-updated-os-checkmate-9er (Oq Updated Os Checkmate 9er)

Kaplan-Meier curve depicting overall survival probability over time (months) comparing two treatment groups: Nivolumab + Cabozantinib and Sunitinib. The graph includes the number of subjects at risk for each group at various time points from 0 to 45 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.